Skip to main content Skip to navigation

[University home]

School of Medicine

Professor Tim Illidge BSc PhD MRCP FRCR

Professor of Targeted Therapy and Oncology

  • Email: tmi@manchester.ac.uk
  • Telephone: +44 (0)161 446 8110
  • Alternative Telephone: +44 (0)161 446 3473 (PA - Roberta Ellis)
  • Fax: 0161 446 8111

School of Cancer and Enabling Sciences
Faculty of Medical & Human Sciences
University of Manchester
Radiotherapy Related Research, Floor 2A
The Christie NHS Foundation Trust
Wilmslow Road
Manchester
M20 4BX

 

Role

Cancer Research UK Senior Clinical Research Fellow and Consultant in Oncolology at Christie Hospital NHS Foundation Trust

 

Research

The research aims of the Targeted Therapy Group are to increase our understanding of the interactions between monoclonal antibodies mAb) and irradiation in the treatment of cancer and to develop novel clinical trial protocols using radionuclide targeted therapies. There are two research domains which inter-relate to form a cohesive programme of preclinical work under the title of radioimmunotherapy (RIT) of cancer, which include optimisation of RIT and irradiation and immunoregulation. In the first project, the roles of mAb as both vectors to deliver radiotherapy to tumours and in direct cancer cell killing are further explored. The specific aims are to further understand the mechanisms of action of RIT and define the relative contributions of targeted radiation and mAb effector mechanisms to the clearance of tumour. In the second project, mAb are used to augment Tcell responses to tumour by blocking or stimulating coreceptors in the immune system. This project aims to further define the factors which are important in combining irradiation and immunoregulatory mAb.

 

Publications

2012

  • Jamie Honeychurch*, Waleed Alduaij*, Mahsa Azizyan, Eleanor J. Cheadle, Helene Pelicano, Andrei Ivanov, Peng Huang , Mark S. Cragg, and Tim M. Illidge. (In-press). Antibody-induced non-apoptotic cell death is mediated through the generation of reactive oxygen species by NADPH oxidase in human lymphoma and leukemia cells. Blood, eScholarID:152478

2011

  • Alduaij, W. & Illidge, T (2011). The future of anti-CD20 monoclonal antibodies: are we making progress? Blood, 117(11), 2993-3001. eScholarID:133388 | PMID:21209380 | DOI:10.1182/blood-2010-07-298356
  • Alduaij, W., Ivanov, A., Honeychurch, J., Cheadle, E., Potluri, S., Lim, S., Shimada, K., Chan, C., Tutt, A., Beers, S., Glennie, M., Cragg, M. & Illidge, T (2011). Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood, 117(17), 4519-29. eScholarID:133394 | PMID:21378274 | DOI:10.1182/blood-2010-07-296913
  • Harrington, K., Billingham, L., Brunner, T., Burnet, N., Chan, C., Hoskin, P., Mackay, R., Maughan, T., Macdougall, J., McKenna, W., Nutting, C., Oliver, A., Plummer, R., Stratford, I. & Illidge, T (2011). Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. Br J Cancer, 105(5), 628-39. eScholarID:141841 | PMID:21772330 | DOI:10.1038/bjc.2011.240
  • Illidge, T. & Morschhauser, F (2011). Radioimmunotherapy in follicular lymphoma. Best Pract Res Clin Haematol, 24(2), 279-93. eScholarID:141842 | PMID:21658624 | DOI:10.1016/j.beha.2011.03.005
  • Lowry, L., Smith, P., Qian, W., Falk, S., Benstead, K., Illidge, T., Linch, D., Robinson, M., Jack, A. & Hoskin, P (2011). Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol, 100(1), 86-92. eScholarID:141843 | PMID:21664710 | DOI:10.1016/j.radonc.2011.05.013
  • Mayes, S., Brown, N. & Illidge, T (2011). New antibody drug treatments for lymphoma. Expert Opin Biol Ther, 11(5), 623-40. eScholarID:133377 | PMID:21395497 | DOI:10.1517/14712598.2011.560569
  • Mayes, S., Brown, N. & Illidge, T (2011). New antibody drug treatments for lymphoma. Expert Opin Biol Ther, 11(5), 623-40. eScholarID:133392 | PMID:21395497 | DOI:10.1517/14712598.2011.560569
  • Naidoo, K., Clay, V., Hoyland, J., Swindell, R., Linton, K., Illidge, T., Radford, J. & Byers, R (2011). YY1 expression predicts favourable outcome in follicular lymphoma. J Clin Pathol, 64(2), 125-9. eScholarID:133383 | PMID:21109702 | DOI:10.1136/jcp.2010.078188

2010

  • Hampson, G., Ward, T., Cummings, J., Bayne, M., Tutt, A., Cragg, M., Dive, C. & Illidge, T (2010). Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects. J Immunol Methods, 360(1-2), 30-8. eScholarID:133396 | PMID:20547164 | DOI:10.1016/j.jim.2010.05.009
  • Illidge, T (2010). Radioimmunotherapy of lymphoma: a treatment approach ahead of its time or past its sell-by date? J Clin Oncol, 28(18), 2944-6. eScholarID:133389 | PMID:20458052 | DOI:10.1200/JCO.2009.26.8748

2009

  • Alduaij, W. & Illidge, T (2009). Radioimmunotherapy: strategies for the future in indolent and aggressive lymphoma. Curr Oncol Rep, 11(5), 363-70. eScholarID:133390 | PMID:19679011 | DOI:10.1007/s11912-009-0049-8
  • Andrei Ivanov, Stephen A Beers, Claire Walshe, Jamie Honeychurch, Waleed Alduaij, Kerry L Cox, Stephen Murray, Claude HT Chan, Jekaterina Erenpreisa, Martin J Glennie, Tim M Illidge, Mark S Cragg. (2009). Mechanism of non-apoptotic cell death evoked by Type II anti-CD20 (Tositumomab) and HLA-DR monoclonal antibodies. J Clinical Investigation, 119(8), 2143-2159. eScholarID:69138 | DOI:10.1172/JCI37884
  • Illidge TM, Du Y. (2009). When is a predose a dose too much? Blood, 113( 23), eScholarID:1d20998 | DOI:10.1182/blood-2009-03-208918
  • Illidge, T., Bayne, M., Brown, N., Chilton, S., Cragg, M., Glennie, M., Du, Y., Lewington, V., Smart, J., Thom, J., Zivanovic, M. & Johnson, P (2009). Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood, 113(7), 1412-21. eScholarID:133391 | PMID:19074729 | DOI:10.1182/blood-2008-08-175653
  • Illidge, TM, Bayne, M, Brown, N, Chilton, S, Cragg, M, Glennie, M, Du, Y, Lewington, V, Smart, J, Thom, J, Zivanovic, M, Johnson, P. (2009). Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood, 113( 7), eScholarID:1d32452 | DOI:10.1182/blood-2008-08-175653
  • Ivanov, A., Beers, S., Walshe, C., Honeychurch, J., Alduaij, W., Cox, K., Potter, K., Murray, S., Chan, C., Klymenko, T., Erenpreisa, J., Glennie, M., Illidge, T. & Cragg, M (2009). Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest, 119(8), 2143-59. eScholarID:133393 | PMID:19620786 | DOI:10.1172/JCI37884
  • Waleed Alduaij and Tim M. Illidge. (2009). Radio-Immunotherapy: Strategies for the future in indolent and aggressive lymphoma. Current oncology reports, 11(5), 363-370. eScholarID:69145 | DOI:10.1007/s11912-009-0049-8

2008

  • Illidge T and Bayne M. (2008). Radioimmunotherapy in haematological cancer. Treatment of Cancer. (pp. 202-225). London, UK: Hodder Arnold. eScholarID:83846
  • Byers RJ, Sakhinia E, Joseph P, Glennie C, Hoyland JA, Menasce L, Radford JA, Illidge TM. (2008). Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. Blood, 111( 9), eScholarID:1d18683 | DOI:10.1182/blood-2007-10-115915
  • Byers, R., Sakhinia, E., Joseph, P., Glennie, C., Hoyland, J., Menasce, L., Radford, J. & Illidge, T (2008). Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. Blood, 111(9), 4764-70. eScholarID:133380 | PMID:18174380 | DOI:10.1182/blood-2007-10-115915
  • Erenpreisa, J, Ivanov, A, Wheatley, S, Kosmacek, E, Ianzini, F, Anisimov, A, Mackey, M, Davis, P, Plakhins, G, Illidge, TM. (2008). Endopolyploidy in irradiated p53-deficient tumour cell lines: persistence of cell division activity in giant cells expressing Aurora-B kinase. Cell Biol Int, 32( 9), eScholarID:1d32547 | DOI:10.1016/j.cellbi.2008.06.003
  • Illidge TM, Chan C. (2008). How have outcomes for patients with follicular lymphoma changed with the addition of monoclonal antibodies? Leuk Lymphoma, 49( 7), eScholarID:1d21004 | DOI:10.1080/10428190802090805
  • Illidge TM, Tolan S. (2008). Current treatment approaches for diffuse large B-cell lymphoma. Leuk Lymphoma, 49( 4), eScholarID:1d21006 | DOI:10.1080/10428190701882187
  • Ivanov A, Krysov S, Cragg M, Illidge TM. (2008). Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis. Clin Cancer Res, 14( 15), eScholarID:1d20997 | DOI:10.1158/1078-0432.CCR-07-5072
  • Ivanov A, Swann RR, Illidge TM. (2008). New insights into the mechanisms of action of radioimmunotherapy in lymphoma. J Pharm Pharmacol, 60( 8), eScholarID:1d21003 | DOI:10.1211/jpp.60.8.0006
  • Zinzani PL, d'Amore F, Bombardieri E, Brammer C, Codina JG, Illidge T, Jurczak W, Linkesch W, Morschhauser F, Vandenberghe E, Van Hoof A. (2008). Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop. European Journal of Cancer, 44(3), 366-373. eScholarID:69149 | DOI:10.1016/j.ejca.2007.12.008

2007

  • Illidge T and Hainsworth J. (2007). Innovative leukaemia and lymphoma. Taylor and Francis Group. eScholarID:83841
  • Price PM, K Sikora, Illidge TM. (2007). Treatment of Cancer (5th Edition edn). eScholarID:4d146
  • Illidge T and Bayne M. (2007). Radioimmunotherapy in haematological malignancy. Advances in Nuclear Oncology : Diagnosis and Therapy. UK: Informa UK Healthcare. eScholarID:83850
  • Du Y, Cullum I, Illidge TM, Ell P. (2007). Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol, 25( 23), 3440-7. eScholarID:1d31668
  • Du Y, Honeychurch J, Glennie M, Johnson P, Illidge TM. (2007). Microscopic intratumoral dosimetry of radiolabeled antibodies is a critical determinant of successful radioimmunotherapy in B-cell lymphoma. Cancer Res, 67( 3), eScholarID:1d31340
  • Kim, Y, Duvic, M, Obitz, E, Gniadecki, R, Iversen, L, Osterborg, A, Whittaker, S, Illidge, TM, Schwarz, T, Kaufmann, R, Cooper, K, Knudsen, K, Lisby, S, Baadsgaard, O, Knox, S. (2007). Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood, 109(11), 4655-62. eScholarID:1d31440
  • Kim, Y., Duvic, M., Obitz, E., Gniadecki, R., Iversen, L., Osterborg, A., Whittaker, S., Illidge, T., Schwarz, T., Kaufmann, R., Cooper, K., Knudsen, K., Lisby, S., Baadsgaard, O. & Knox, S (2007). Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood, 109(11), 4655-62. eScholarID:133376 | PMID:17311990 | DOI:10.1182/blood-2006-12-062877
  • Morschhauser, F, Illidge, TM, Huglo, D, Martinelli, G, Paganelli, G, Zinzani, P, Rule, S, Liberati, A, Milpied, N, Hess, G, Stein, H, Kalmus, J, Marcus, R. (2007). Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood, 110( 1), eScholarID:1d31711

2006

  • Illidge T and Du Y. (2006). Radioimmunotherapy in lymphoma. Radiotherapy in practice : Volume III Radioisotopes. (pp. 121-152). UK: Oxford University Press. eScholarID:83843
  • Kalejs M, Ivanov A, Plakhins G, Cragg M, Emzinsh D, Illidge TM, Erenpreisa J. (2006). Upregulation of meiosis-specific genes in lymphoma cell lines following genotoxic insult and induction of mitotic catastrophe. BMC Cancer, 6, eScholarID:1d30339
  • Kalejs, M., Ivanov, A., Plakhins, G., Cragg, M., Emzinsh, D., Illidge, T. & Erenpreisa, J (2006). Upregulation of meiosis-specific genes in lymphoma cell lines following genotoxic insult and induction of mitotic catastrophe. BMC Cancer, 6, 6. eScholarID:133395 | PMID:16401344 | DOI:10.1186/1471-2407-6-6
  • Weigert O, Illidge TM, Hiddemann W, Dreyling M. (2006). Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma. Cancer, 107( 4), eScholarID:1d21007 | DOI:10.1002/cncr.22066

2005

  • Tim Illidge and Peter W M Johnson. (Ed.) (2005). Lymphoma Methods and Protocols. Totowa, New Jersey: Humana press. eScholarID:83848
  • Erenpreisa J, Kalejs M, Ianzini F, Kosmacek E, Mackey M, Emzinsh D, Cragg M, Ivanov A, Illidge TM. (2005). Segregation of genomes in polyploid tumour cells following mitotic catastrophe. Cell Biol Int, 29( 12)(12), 1005-1011. eScholarID:1d30291
  • Geldart T, Illidge TM. (2005). Anti-CD 40 monoclonal antibody. Leuk Lymphoma, 46( 8), eScholarID:1d21008 | DOI:10.1080/10428190500085255
  • Geldart, T. & Illidge, T (2005). Anti-CD 40 monoclonal antibody. Leuk Lymphoma, 46(8), 1105-13. eScholarID:133379 | PMID:16085550 | DOI:10.1080/10428190500085255
  • Honeychurch J, Glennie M, Illidge TM. (2005). Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells. Cancer Res, 65( 16), 7493-501. eScholarID:1d11454 | DOI:10.1158/0008-5472.CAN-04-3808
  • Honeychurch, J., Glennie, M. & Illidge, T (2005). Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells. Cancer Res, 65(16), 7493-501. eScholarID:133381 | PMID:16103104 | DOI:10.1158/0008-5472.CAN-04-3808
  • Illidge TM. (2005). Anti-CD40: Janus or gatekeeper? Blood, eScholarID:1d33854
  • McFarlane V, Friedmann P, Illidge TM. (2005). What's new in the management of cutaneous T-cell lymphoma? Clin Oncol (R Coll Radiol), 17( 3), 174-84. eScholarID:1d30340
  • McFarlane, V., Friedmann, P. & Illidge, T (2005). What's new in the management of cutaneous T-cell lymphoma? Clin Oncol (R Coll Radiol), 17(3), 174-84. eScholarID:133382 | PMID:15901002

2004

  • Cragg M, Bayne M, Illidge TM, Valerius T, Johnson P, Glennie M. (2004). Apparent modulation of CD20 by rituximab: an alternative explanation. Blood, 103( 10), 3989-90; author reply 3990-1. eScholarID:1d29475
  • Cragg M, Bayne M, Tutt A, French R, Beers S, Glennie M, Illidge TM. (2004). A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells. Blood, 104( 8), eScholarID:1d9442 | DOI:10.1182/blood-2004-05-1733
  • Du Y, Honeychurch J, Cragg M, Bayne M, Glennie M, Johnson P, Illidge TM. (2004). Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood, 103( 4), 1485-94. eScholarID:1d9444 | DOI:10.1182/blood-2003-06-2037
  • Meyers, C, Smith, J, Bezjak, A, Mehta, M, Liebmann, J, Illidge, TM, Kunkler, I, Caudrelier, J, Eisenberg, P, Meerwaldt, J, Siemers, R, Carrie, C, Gaspar, L, Curran, W, Phan, S, Miller, R, Renschler, M. (2004). Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol, 22( 1), 157-65. eScholarID:1d28800

2003

  • Honeychurch J, Glennie M, Johnson P, Illidge TM. (2003). Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. Blood, 102( 4), 1449-57. eScholarID:1d9445 | DOI:10.1182/blood-2002-12-3717
  • Honeychurch, J., Glennie, M., Johnson, P. & Illidge, T (2003). Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. Blood, 102(4), 1449-57. eScholarID:133378 | PMID:12714523 | DOI:10.1182/blood-2002-12-3717
  • Ivanov A, Cragg M, Erenpreisa J, Emzinsh D, Lukman H, Illidge TM. (2003). Endopolyploid cells produced after severe genotoxic damage have the potential to repair DNA double strand breaks. J Cell Sci, 116( Pt 20), 4095-106. eScholarID:1d29505

2002

  • Erenpreisa J, Ivanov A, Cragg M, Selivanova G, Illidge TM. (2002). Nuclear envelope-limited chromatin sheets are part of mitotic death. Histochem Cell Biol, 117( 3), 243-55. eScholarID:1d30715
  • McFarlane V, Clein G, Cole J, Cowley N, Illidge TM. (2002). Cervical neuropathy following mantle radiotherapy. Clin Oncol (R Coll Radiol), 14( 6), 468-71. eScholarID:1d29426

2001

  • Bayne M, Illidge TM. (2001). Hypercalcaemia, parathyroid hormone-related protein and malignancy. Clin Oncol (R Coll Radiol), 13( 5), 372-7. eScholarID:1d28799
  • Illidge TM, Bayne M. (2001). Antibody therapy of lymphoma. Expert Opin Pharmacother, 2( 6), 953-61. eScholarID:1d29427

Top of page

| Skip to main content | Skip to navigation | Skip to Search |